CAPR Deadline: Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Losses to Contact the Firm for Information About Their Rights

Core Viewpoint - Rosen Law Firm is urging investors of Capricor Therapeutics, Inc. to contact them regarding a class action lawsuit due to alleged misleading information about the company's business operations and its lead drug candidate, deramiocel [1][2][3]. Summary by Sections Allegations - The lawsuit claims that Capricor provided investors with misleading information about deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [3]. - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the safety and efficacy data from the Phase 2 HOPE-2 trial [3]. Class Action Participation - Shareholders wishing to serve as lead plaintiffs must file motions by September 15, 2025, and can remain absent class members if they choose not to participate [4]. - The law firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. About Rosen Law Firm - Rosen Law Firm is recognized for its leadership in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].